Compare Recursion Pharmaceuticals Inc (RXRX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B), while United States Natural Gas Fund trades at $11.12 (market cap $517.27M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.1× United States Natural Gas Fund's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and United States Natural Gas Fund for 22 Days on average.
| RXRX | UNG | |
|---|---|---|
Market Cap | $2.14B | $517.27M |
Volume | 30,789,535 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $6.79 | $16.90 |
52-Week Low | $2.84 | $9.63 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
UNG trades at $11.06, up 0.28% with a bullish technical signal from moving averages. The fund reported $65.15M net income for 2024 despite zero revenue, with strong total assets of $790.02M and minimal debt. Recent news highlights natural gas market volatility with record production and geopolitical tensions influencing energy prices.
The outlook is mixed: technical strength and clean balance sheet support stability, but zero revenue and negative cash flow (-$251.70M) pose fundamental risks. Investors face exposure to natural gas price swings and supply-demand imbalances, requiring careful monitoring of energy market developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
